CANTON, Mass., July 13, 2017 /PRNewswire/ — PuraPlyTM Antimicrobial (PuraPlyTM AM), an FDA 510(k)-cleared wound management product from Organogenesis Inc., has been named one of the “Top 10 Innovations in Podiatry” by Podiatry Today, an award-winning publication that covers the latest developments in podiatric medicine.
PuraPly AM was selected as a top innovation for 2017 for its impact on reducing bioburden in wounds.
It is estimated that the majority of wounds possess biofilm, which can negatively impact tissue repair and delay healing if not addressed. With PuraPly AM, clinicians have a product solution to specifically address this challenge.
“A lot of times, debridement alone isn’t enough to prevent the reformation of biofilm,” said Ryan Fitzgerald, DPM, FACFAS, Associate Professor of Surgery at the University of South Carolina School of Medicine, in the article from Podiatry Today. “As part of a comprehensive biofilm-based wound management approach including sharp debridement, PuraPly AM provides a barrier that helps prevent biofilm re-formation and supports healing.”
PuraPly AM is an FDA 510(k)-cleared Class II medical device that is intended for management of a variety of acute and chronic wound types, including partial- and full-thickness wounds, pressure ulcers, surgical wounds, trauma wounds, venous and diabetic ulcers. PuraPly AM is unique in that it combines purified native collagen with PHMB, which provides broad antimicrobial coverage and protects against a wide range of bacteria that colonize wounds and can progress to biofilm formation and infection.
“Developing and manufacturing innovative products that serve our customers’ needs is at the heart of what we do, so it’s an honor for PuraPly AM to receive this distinction,” said Gary S. Gillheeney, Sr., President & CEO of Organogenesis Inc. “We’re pleased about the extremely positive reception this product has received since its 2015 launch and look forward to helping more wound care clinicians utilize PuraPly AM in the fight against bioburden and infection.”
For more information on PuraPly AM, click here.
About Organogenesis Inc.
Headquartered in Canton, Massachusetts, Organogenesis Inc. is a global leader in regenerative medicine, offering a portfolio of bioactive and acellular biomaterials products in advanced wound care and surgical biologics, including orthopedics and spine. Organogenesis’ versatile portfolio is designed to treat a variety of patients with repair and regenerative needs. For more information, visit www.organogenesis.com.
SOURCE Organogenesis Inc.